BIAHDBioimpedance Versus Clinical Methods in Guiding Ultrafiltration in Hemodialysis Patients: a Randomized Trial
Strict bioimpedance guided dry weight prescription
Étude thérapeutique
Résumé
Date de début de l'étude : 1 juillet 2008
Date à laquelle le premier participant a commencé l'étude.The investigators developed a randomized controlled study to compare exclusively bioimpedance guided ultrafiltration in hemodialysis patients versus traditional methods for volume assessment. The duration of the study was 3,5 years. During the first 2,5 years of the study all enrolled patients were randomized using a block randomization algorithm in two arms. In the interventional arm the post-dialysis dry weight was prescribed exclusively using the BCM device (Body Composition Monitor - Fresenius Medical Care, Germany). In the control arm dry weight assessment was done by traditional clinical methods. In both arms,during the intervention period (2,5 years) BCM measurements were performed every 3 months before dialysis, but only in the interventional arm the values were disclosed to the medical personnel and used to guide the dry weight and ultrafiltration volumes. In the control arm (clinical), both patients and caregivers were fully blinded from the BCM results. The BCM device measures for each patient an ideal dry weight interval ( +/- 1.1 kg). In the interventional arm, the prescribed dry weights of the patients were strictly maintained in the ideal weight interval (+/- 1.1 kg) proposed by the BCM device. Primary outcome was all cause-mortality compared in the strict bioimpedance arm versus the clinical (control) arm and was assessed at 2,5 years. Secondary end-points, assessed during the randomization period (2,5 years), were to compare blood pressure (determined pre dialysis), arterial stiffness and relative fluid overload (RFO = overhydration/ total body water), as measured by the BCM device. During the last year of the study, all patients were left free of any intervention, and only arterial stiffness was assessed a third time at 3,5 years.
Protocole
Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.131 participants à inclure
Nombre total de participants que l'essai clinique vise à recruter.Traitement
Éligibilité
Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.Tout sexe
Le sexe biologique des participants éligibles à s'inscrire.À partir de 18 ans
Tranche d'âge des participants éligibles à participer.Volontaires sains non autorisés
Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.Critères
Inclusion Criteria: older than 18-year on chronic hemodialysis for more than 3 months Exclusion Criteria: - life expectancy of less than 1 year Presence of a condition that may interfere with the determination of dry weight using the Body Composition Monitor (R): severe ascites (decompensated liver failure) limb amputations cardiac stent, pacemaker or defibrillator hip prosthetic pregnancy mental deficiency (impossibility to give consent)
Plan de l'étude
Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.2 groupes d'intervention sont désignés dans cette étude
Cette étude ne comporte pas de groupe placebo.
Groupes de traitement
Groupe I
Pas d'interventionGroupe II
Comparateur actifObjectifs de l'étude
Objectifs principaux
Objectifs secondaires